To review the clinical management of Tourette's syndrome (TS) and the associated disorders, namely obsessive-compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD) with an emphasis on the pharmacologic intervention strategies.
Method
English language literature on the pharmacologic management of TS and the associated disorders published between 1985 and 1994 was critically reviewed.
Results
Pharmacologic management was placed in the context of the overall clinical management. Pharmacologic strategies for treatment of TS, OCD and ADHD were organized according to the therapeutic agent class.
Conclusions
The treatment of TS and its associated disorders requires the application of the full range of psychiatric skills to achieve a favourable outcome.
References
1.
American Psychiatric Association.Diagnostic and statistical manual of mental disorders.4th ed.Washington DC: American Psychiatric Association,1994.
2.
LangA.Patient perception of tics and other movement disorders.Neurology1991; 41: 223–228.
3.
RobertsonM.M., TrimbleM.R., LeesA.J.The psychopathology of the Gilles de la Tourette syndrome.Br J Psychiatry1988; 152: 383–390.
4.
PaulsD.L., LeckmanJ.F.The inheritance of Gilles de la Tourette's syndrome and associated behaviours: evidence for autosomal dominant transmission. N Engl J.Med1986; 315: 993–997.
5.
CummingsD.E.A controlled study of Tourette syndrome VIII — summary: a common genetic disorder causing disinhibitation of the limbic system.Am J Hum Genet1987; 41: 839–866.
6.
SingerH.S., ReissA.L., BrownJ.E.Volumetric MRI changes in basal ganglia of children with Tourette's syndrome.Neurology1993; 43: 950–956.
7.
PetersonB., RiddleM.A., CohenD.J.Reduced basal ganglia volumes in Tourette's syndrome using tree magnetic resonance images.Neurology1993; 43: 941–949.
8.
LeckmanJ.F., PattersonB.S.The pathogenesis of Tourette's syndrome: epigenetic factors active in early CMS development.Biol Psychiat1993; 34: 425–427.
9.
PaulsD.L., TwobinK.E., LeckmanJ.F.Gilles de la Tourette syndrome and obsessive-compulsive disorder: evidence supporting a genetic relationship.Arch Gen Psychiatry1986; 43: 1180–1182.
10.
MatthewsW.S.Attention deficit and learning disabilities in children with Tourette's syndrome.Psychiatric Annals1988; 8: 414–416.
11.
RandolphC., HydeT.M., GoldJ.M.Tourette syndrome in monozygotic twins: relationship of tic severity to neuropsychologic function.Arch Neurol1993; 50: 725–728.
12.
HydeT.M., EmsellemH.A., RandolphC.Electroencephalographic abnormalities in monozygotic twins, with Tourette's syndrome.Br J Psychiat1994; 164: 811–817.
13.
ThibertA.L., DayH.L., SandorP.Self-concept and self-conscientiousness in adults with Tourette syndrome.Can J Psychiatry1995; 40: 35–39.
14.
LeckmanJ.F., RiddleM.A., HardinM.T.The Yale Global Tic Severity Scale: initial testing of a clinician — rated scale of tic severity.J Am Acad Child Adolesc Psychiatry1989; 28: 566–573.
15.
GoodmanW.K., PriceL.H., RasmussenS.A.The Yale-Brown Obsessive-Compulsive Scale: I, Development, Use and Reliability.Arch Gen Psychiatry1989; 46: 1006–1011.
16.
GoyetteC., ConnersC.K., UlrichR.Normative data on revised Conners' parent and teacher rating scales.J Abnorm Child Psychol1978; 6: 221–236.
17.
KurlanR., BehrJ., MedvedL.Severity of Tourette's Syndrome in one large kindred: implications of determination of disease prevalence rate.Arch Neurol1987; 44: 268–269.
18.
ErenbergG.Pharmacologic therapy of tics in childhood.Psychiatr Ann1988; 399–408.
19.
BruunR.O.Subtle and under-recognized side effect of neuroleptic treatment in children with Tourette's disorder.Am J Psychiatry1988; 145: 621–624.
20.
ShapiroE., ShapiroA.K., FulopG.Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome.Arch Gen Psychiatry1989; 722–730.
21.
MikkelsenE.J., DetlorJ., CohenD.J.School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder.Am J Psychiatry1981; 138: 1572–1575.
22.
LinetL.S.Tourette syndrome, pimozide and school phobia: the neuroleptic separation anxiety syndrome.Am J Psychiatry1985; 142: 613–615.
23.
RiddleM.A., HardinM.T., TowbinK.E.Tardive dyskinesia following haloperidol treatment in Tourette's syndrome.Arch Gen Psychiatry1987; 44: 98–99.
24.
FulopG., PhillipsR.A., ShapiroA.K.EEG changes during haloperidol and pimozide treatment of Tourette's disorder.Am J Psychiatry1987; 44: 673–675.
25.
GouldR.J., MurphyM.M., ReynoldsL.J.Antischizophrenic drugs of the diphenylbutyl-piperidine type act as calcium channel antagonists.Proc Natl Acad Sci1983; 80: 5122–5125.
26.
RemingtonG.J.Clinical considerations in the use of risperidone.Can J Psychiatry1993; 38(S3): S96–S100.
27.
RossB.Personal communication, 1994.
28.
RemingtonG., AdamsM.Risperidone and obsessive-compulsive symptoms.J Clin Psychopharmacol1994; 14: 358–359.
29.
LeckmanJ.F., WalkupJ.T., CohenD.J.Clonidine treatment of Tourette's syndrome. In: CohenD.J., BruunR.D., LeckmanJ.F., editors. Tourette's syndrome and tic disorders: clinical understanding and treatment.New York: Wiley;1988.
30.
KainA.A case of Gilles de la Tourette's syndrome treatment with clonazepam.Brain Research1983; 11: 213–214.
31.
TruongD.D., BressmanS., ShaleH.Clonazepam, haloperidol and Clonidine in tic disorders.South Med J1988; 81: 1103–1105.
32.
ZoharJ., InselT.R.Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology.Biol Psychiatry1987; 22: 667–687.
33.
GoodmanW.K., PriceL.H., DelgadoP.L.Specificity of serotonin reuptake inhibition in the treatment of obsessive-compulsive disorders.Arch Gen Psychiatry1990; 47: 577–585.
34.
LeonardH., SwedoS., RappoportJ.L.Treatment of childhood obsessive-compulsive disorder with clomipramine and desmethyl imipramine: a double-blind crossover comparison.Psychopharmacol Bull1988; 24: 93–95.
35.
ChouinardG., GoodmanW., GreistJ.H.Results of a double blind trial of a sertonin uptake inhibitor sertraline in the treatment of obsessive-compulsive disorder.Psychopharmacol Bull1990; 26: 279–284.
MontgomeryS.A., ManceauxA.Fluvoxamine in treatment of obsessive-compulsive disorder.Int Clin Psychopharmacol1992; 7(1 Suppl): 5S–9S.
38.
TeichnerM.H., GlodC., ColeJ.O.Emergence of intense suicidal preoccupation during fluoxetine treatment.Am J Psychiatry1990; 147: 207–210.
39.
BeasleyC.M., DornseifB.E., BossomworthJ.C.Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.Br Med J1991; 303: 685–692.
40.
FavaM., RosenbaumJ.F.Suicidality and fluoxetine; is there a relationship?J Clin Psychiatry1991; 52: 108–111.
41.
RiddleM.A., HardinM.T., KingR.Fluoxetine treatment of children and adolescents with Tourette and obsessive-compulsive disorders: preliminary clinical experience.J Am Acad Child Adolesc Psychiatry1900; 29: 45–48.
42.
McDougleC.J., GoodmanW.K., LeckmanJ.F.The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of chronic tic disorder.J Clin Psychopharmacol1993; 13: 354–358.
43.
GoodmanW.K., McDougleC.J., PriceL.H.The role of serotonin and dopamine in the pathophysiology of obsessive-compulsive disoroder.Int Clin Psychopharmacol1992; (1 Suppl): 35S–38S.
44.
ShapiroA.K., ShapiroE.Do stimulants provoke, cause, or exacerbate tics and Tourette syndrome?Comp Psychiatry1981; 22: 265–273.
45.
PriceA.R., LeckmanJ.F., PaulsD.L.Gilles de la Tourette's syndrome: tics and central nervous system stimulants.Neurology1986; 36: 232–237.
46.
SverdJ., GadowK.D., PaolicelliL.M.Methylphenidate treatment of attention deficit hyperactivity disorder in boys with Tourette's syndrome.J Am Acad Child Adolesc Psychiatry1989; 28: 574–579.
47.
CampbellM., GreenW.H., DeutschS.I.Child and adolescent psychopharmacology.Beverly Hills CA: Sage; 1985.
48.
BiedermanJ., BaldessariniR.J., WrightV.A double-blind placebo-controlled study of desipramine in the treatment of ADD: I. Efficacy.J Am Acad Child Adolesc Psychiatry1989; 28: 777–784.
49.
RiddleM.A., HardinM.T., ChoS.C.Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experiences.J Am Acad Child Adolesc Psychiatry1988; 27: 811–814.
50.
WenderP.H.Attention deficit hyperactivity disorder In: HowelsJ.G., editor. Modern perspectives in clinical psychiatry.New York: Brunner/Maze; 1988: 149–169.
51.
GreenW.H.Child and adolescent clinical psychopharmacology.Baltimore: Williams & Wilkins; 1991.
52.
RobertsonM.M., EapenV.Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome.Clinical Neuropharmacol1992; 15: 408–425.
53.
DuncanM.K.Using psychostimulants to treat behavioural disorder of children and adolescentsJ Child Adolesc Psychopharmacol1990; 1: 7–20.
54.
GolinkoB.E.Side effects of dextroamphetamine and methylphenidate in hyperactive children — a brief review.Prog Neuro-psycho-pharmacol Biol Psychiatry1984; 8: 1–88.
ShafferD.Attention deficit hyperactivity disorder in adults.Am J Psychiatry1994; 151: 633–638.
57.
WenderP.H., ReimherrF.W.A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type adults.Am J Psychiatry1985; 142: 547–552.
58.
WardM.F., WenderP.H., ReimmherrF.W.The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder.Am J Psychiatry1993; 150: 885–890.
